Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29622593 | 0.86 | KDM4E (0.34) | KDM4EALDH1A1HPGDKMT2ANPSR1 | |
| SCHEMBL565470 | 0.86 | KDM4E (0.34) | KDM4EALDH1A1HPGDKMT2ANPSR1 | |
| SCHEMBL101482 | 0.84 | DGAT1 (0.33) | KDM4EALDH1A1DGAT1KDM1ANPC1 | |
| SCHEMBL22620183 | 0.82 | DGAT1 (0.40) | DGAT1NPC1MAPT | |
| SCHEMBL2395822 | 0.80 | KDM1A (0.35) | KDM4EALDH1A1HPGDKMT2ANPSR1 | |
| SCHEMBL10099308 | 0.79 | DGAT1 (0.34) | DGAT1NPC1MAPT | |
| SCHEMBL18975742 | 0.79 | KDM1A (0.35) | KDM4EALDH1A1HPGDKMT2ANPSR1 | |
| SCHEMBL2884544 | 0.78 | DGAT1 (0.35) | DGAT1NPC1MAPTKDR | |
| SCHEMBL30877329 | 0.78 | DGAT1 (0.39) | ALDH1A1KMT2ADGAT1LMNAMAPT | |
| SCHEMBL566551 | 0.77 | LMNA (0.40) | KDM4EALDH1A1HPGDKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2420502-A1 | FUSED PYRROLOPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | JAK2, JAK1, JAK3 | KDM4E 2680/4885ALDH1A1 2641/4885HPGD 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.